Bank of America heads into its May 4 Q1 results with short sellers quietly unwinding and the analyst community in a markedly more constructive mood than it was just three weeks ago.
The most telling shift is in the Street's posture after Q1 earnings landed on April 15. Multiple firms raised price targets in the immediate aftermath — Keefe Bruyette lifted to $64, Evercore ISI and Oppenheimer both moved to $61, and Truist Securities raised to $61 with a Buy. The cluster of upgrades came fast, within hours of the print, a sign of genuine conviction rather than routine housekeeping. The mean consensus target now stands at $62.93, roughly 20% above the current close of $52.66. JPMorgan had cut its target to $57.50 on April 7 amid broader macro anxiety, but even that move preserved an Overweight rating — the Street's directional lean is clearly bullish, even if individual estimates are anchored around different macro assumptions. The bull case centres on 7.2% revenue growth, 9% net interest income expansion, and a 21% year-on-year rise in consumer banking net income. The bear case is more pointed: CET1 fell to 11.2% and the supplementary leverage ratio dipped to 5.5%, raising capital adequacy questions in an environment where recession risk remains live.
Short positioning tells a far less aggressive story. SI eased to roughly 1.4% of free float — a level that barely registers as a real directional bet against a bank of this size. More notably, it has been falling. Shorts peaked near 110 million shares in late March, then stepped down through April, with the largest single-day drop arriving on April 23 when the position shed roughly 4.3 million shares in one session. The weekly decline now runs close to 5.7%. With a days-to-cover below one and a short score of just 30.6 out of 100, the lending market is under no strain. Borrow cost ticked up to 0.41% on April 28 from a mid-week low around 0.14%, but that jump looks like settlement noise rather than demand pressure — it remains well below the 0.69% printed in late March. Availability remains ample, with no sign of tightening that would signal fresh shorts building meaningfully.
Options positioning adds a modest layer of caution. The put/call ratio edged up to 1.24, slightly above its 20-day average of 1.19 but only 0.86 standard deviations from the mean — well within normal. The 52-week high for the PCR stands at 1.67, and the current reading is closer to the floor (1.08) than the ceiling. That places options sentiment in mildly defensive territory rather than signalling anything alarming. The RSI-14 is a neutral 56.9, consistent with a stock that has recovered sharply — up 12% over the past month — but has not yet entered overbought territory.
On the institutional side, the ownership picture is notable for one name: Berkshire Hathaway, BAC's third-largest holder at 7.3% of shares, trimmed by approximately 50.8 million shares through year-end 2025. That reduction has been well-telegraphed in the market and does not appear to be exerting sustained pressure now. On the other side, Capital Research added 41.3 million shares in Q1 2026, and Vanguard added 23.3 million — net institutional flow looks supportive at the margin. Insider activity is a routine pattern: CEO Brian Moynihan sold shares on April 15 concurrent with an award of the same size, a common vesting-and-sell programme rather than a discretionary disposal. The 90-day net insider position across all executives is marginally positive in share terms, though the dollar value sold across March — COO Tom Scrivener ($2.5m), HR Director Sheri Bronstein ($3.0m), Co-Presidents DeMare and Athanasia — totals well north of $15m in open-market sales. These are sizable in absolute terms but are not unusual at BAC's executive compensation scale.
Looking ahead, the next event on May 4 is positioned as another results-related update, likely a conference or additional management commentary following the April 15 print. The price reaction to that April 15 earnings release was nearly flat on the day (+0.3%), even as the stock gave back 0.4% over the following five sessions — consistent with a solid but fully-priced print. With WFC roughly flat on the week and JPM and C both down slightly, BAC's own -1.5% weekly move tracks the sector rather than diverging from it; regional names like ZION managed a 1.9% gain, suggesting selective appetite for more rate-sensitive exposures. What to watch is whether the CET1 and leverage ratio questions raised in the bear case draw more scrutiny on May 4, or whether the revenue momentum narrative continues to hold the Street's attention.
See the live data behind this article on ORTEX.
Open BAC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
